<DOC>
	<DOCNO>NCT01942941</DOCNO>
	<brief_summary>A study see effect geko™ device blood flow patient low limb vascular disease .</brief_summary>
	<brief_title>Peripheral Vascular Disease Nerve Stimulation</brief_title>
	<detailed_description>The geko™ device , ( CE 558928 ; British Standards Institute notify body 0086 ) , wearable , discrete , self-contained stimulation unit adhere skin ( see www.gekodevices.com ) . The , geko™ trigger small electrical impulse gently activate common peroneal nerve within popliteal fossa , behind knee , turn activate venous muscle pump calf foot . Substantive increase low limb blood flow demonstrate improve arterial , venous microcirculatory blood flow report morbidity . Environmental Conditions The examination carry designated temperature control clinical room Vascular Lab Hull Royal Infirmary . Participants require abstain vigorous exercise , nicotine , caffeine fatty food prior examination . They require wear light garment leg expose . The geko™ device apply outer/ posterior aspect knee whilst subject semi-recumbent , knee flex . The participant give 30 minute quiet , environmentally control room prior commencement measurement enable equilibration . Assessments Participants complete McGill Pain questionnaire prior device activation Participants geko™ device apply whilst semi-recumbent knee flex . The intensity increase visible muscle stimulation evident ( concentric isotonic contraction ) patient tolerance reach - Laser Doppler image use assess microcirculation flow dorsum foot : 1 . Baseline ( rest ) 2 . 5 minute interval geko™ device active 3 . 30 minute follow removal device Laser Doppler flowmetry reproducible , objective , non-invasive measurement use evaluate real time cutaneous blood flow . The low power light conduct via glass fibre probe attach skin scatter movement blood cell induce Doppler shift . This allow information flux cell velocity record . The system use trial Moor Instruments DT-4 main unit integrated bilateral laser . - Ultrasound Doppler arterial flow velocity blood volume flow within femoral artery ( mid thigh ) bilaterally : 1 . Baseline ( rest ) 2 . 30 minute device active - Ultrasound Doppler flow velocity femoral vein ( mid thigh ) bilaterally : 1 . Baseline ( rest ) 2 . 40 minute geko active - Vascular Endothelial Growth Factor ( VEGF ) , Tissue Plasminogen Activator antigen ( TPA antigen ) , Full blood count ( FBC ) Plasminogen activator inhibitor-1 ( PAI-1 ) : 15 ml blood take femoral vein : 1 . Baseline ( rest ) 2 . 45 minute geko™ device active ELISA analysis carry sample ( see appendix ) . Vascular Endothelial Growth Factor - Therapies lead development new , collateral blood vessel , particular interest field peripheral arterial disease narrow blockage exist blood vessel result tissue ischaemia . Vascular endothelial growth factor ( VEGF ) signal protein produce cell stimulate growth new blood vessel pre-existing vessel . Several previous study show electrical stimulation increase VEGF level turn increase vessel density muscle . Tissue plasminogen activator ( tPA ) protein involve breakdown blood clot . As result therapeutic us clinical medicine treat thromboses emboli . Electrical stimulation previously show provoke acute release tPA circulation , although appear response decrease repeat stimulation . Use geko™ device show result significant decrease Tissue Plasminogen Activator ( tPA ) antigen indicative increase fibrinolytic activity . Plasminogen activator inhibitor- 1 ( PAI-1 ) primary inhibitor plasminogen activator inactivate tissue plasminogen activator ( t-PA ) urokinase-type plasminogen activator ( u-PA ) . PAI-1 important inhibitor fibrinolytic system , elevate level could suppress fibrinolysis result increase risk thrombosis . Increased PAI-1 level show associated number atherosclerotic risk factor , PAI-1 show act prothrombic factor arterial venous thromboembolic disorder . - Ankle Brachial Pressure Index baseline post removal geko™- utilising Posterior Tibial Artery Anterior Tibial Artery - Maximum calf circumference baseline post removal geko™ - Three blood pressure heart rate measurement take bilaterally baseline @ 30 minute device active . The mean three value use comparison . - Patient tolerance/ acceptability + Nurse tolerance/ ease application Questionnaire use Visual Analogue Scores Verbal Rating Scores complete follow removal geko™ device ( see appendix ) - The McGill Pain Questionnaire complete follow device removal</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Varicose Veins</mesh_term>
	<criteria>Age &gt; 18 year Absence haematological disorder DVT ( deep vein thrombosis ) precede 12 month Intact cutaneous sensation nocioception lower limb , determine investigator Intact healthy skin site application On effective contraception sexually active oral contraceptive pill ( &gt; 3 month use ) , condom , intrauterine contraceptive device , depot injection Able understand Patient Information Sheet capable willing give inform consent follow protocol requirement History haematological disorder DVT precede 12 month Pregnant plan become pregnant study duration Pacemakers implantable defibrillator Use neuromodulation device Current use TENS ( transcutaneous electrical nerve stimulation ) pelvic region , back legs Use investigational drug/device therapy within past 4 week may interfere study . Significant varicose vein low limb ulceration . Recent surgery ( abdominal , gynaecological , hip knee replacement ) . Recent trauma lower limb . Chronic Obesity ( BMI Index &gt; 34 ) . Any medication judge significant Principal Investigator . Any significant illness four ( 4 ) week precede screen period study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>